After Biocon and Mylan , Reliance Life Sciences has approached the Delhi High Court to appeal against an earlier order that imposed marketing restrictions to its copy of Swiss biotech giant Roche's breast cancer drug , Herclon (trastuzumab).
Reliance's appeal is distinct from Biocon and Mylan's, argued Reliance Life Sciences counsel Pratibha Singh at court on June 3. Reliance was given an injunction before it had launched TrastuRel, whereas CANMAb and Hertraz were already in the market when Roche sued them, she told judges.
The counsel is appealing conditions including restrictions placed on TrastuRel labelling as well as those on using Roche's data, according to Singh.
The April 25 judgement stated that Reliance could also manufacture and market the drug by qualifying the International Non-proprietary Name (INN) Trastuzumab, but couldn't use the name stand alone.
No comments:
Post a Comment